Metabolic engineering of yeast for production of kratom monoterpene indole alkaloids

Maxence Holtz,Daniela Rago,Ida Nedermark,Frederik G. Hansson,Beata J. Lehka,Lea G. Hansen,Nils E. J. Marcussen,Wouter J. Veneman,Linda Ahonen,Juraithip Wungsintaweekul,Ron P. Dirks,Carlos G. Acevedo-Rocha,Jie Zhang,Jay D. Keasling,Michael K. Jensen

DOI: https://doi.org/10.1101/2024.05.22.595370

2024-05-22

Abstract:Monoterpene indole alkaloids (MIAs) from (″kratom″), such as mitragynine and speciogynine, are promising novel scaffolds for opioid receptor ligands for treatment of pain, addiction, and depression. While kratom leaves have been used for centuries in South-East Asia as stimulant and pain management substance, the biosynthetic pathway of these psychoactives have only recently been partially elucidated. Here, we demonstrate the production of mitragynine and speciogynine in through the reconstruction of a five-step synthetic pathway from common MIA precursor strictosidine comprising fungal tryptamine 4-monooxygenase to bypass an unknown kratom hydroxylase. Upon optimizing cultivation conditions, a titer of ≈290 μg/L kratom MIAs from glucose was achieved. Untargeted metabolomics analysis of lead production strains led to the identification of numerous shunt products derived from the activity of strictosidine synthase (STR) and dihydrocorynantheine synthase (DCS), highlighting them as candidates for enzyme engineering to further improve kratom MIAs production in yeast. Finally, by feeding fluorinated tryptamine and expressing a human tailoring enzyme, we further demonstrate production of fluorinated and hydroxylated mitragynine derivatives with potential applications in drug discovery campaigns. Altogether, this study introduces a yeast cell factory platform for the biomanufacturing of complex natural and new-to-nature kratom MIAs derivatives with therapeutic potential.

Synthetic Biology

What problem does this paper attempt to address?

The paper primarily discusses the use of metabolic engineering to reconstruct the yeast Saccharomyces cerevisiae for the synthesis of monoterpenoid indole alkaloids (MIAs) such as mitragynine and speciogynine from scratch. These compounds have potential medicinal value in pain management, addiction treatment, and depression. In this study, the authors developed a biosynthetic pathway consisting of five steps, starting from the common MIA precursor strictosidine and bypassing an unknown kratom hydroxylase through various enzymes in yeast.

By optimizing the culture conditions, the researchers successfully achieved approximately 290 µg/L of kratom MIA from glucose. Through untargeted metabolomic analysis of the leading production strain, they identified several bypass metabolites originating from the strictosidine synthase (STR) and dihydrocorynantheine synthase (DCS) activities, which were marked as candidate targets for enzyme engineering to further improve the production efficiency of kratom MIA. Additionally, by feeding fluorotryptophan and expressing a human modifier enzyme, the researchers demonstrated the production of fluorinated and hydroxylated derivatives of mitragynine, which may have application potential in drug discovery activities.

Overall, this study established a yeast cell factory platform for the production of complex natural and novel natural kratom MIA derivatives with potential therapeutic effects. The research also highlighted the importance of optimizing fermentation conditions to enhance the yield of complex plant natural products, especially at reduced temperatures and using specific carbon source mixtures. Furthermore, through metabolomic analysis, the researchers discovered various bypass metabolites caused by the nonspecificity of STR and DCS, providing directions for improving the biomanufacturing of kratom MIA in yeast.